Cargando…

Semi-Mechanistic Pharmacokinetic-Pharmacodynamic Model of Camostat Mesylate-Predicted Efficacy against SARS-CoV-2 in COVID-19

The SARS-CoV-2 coronavirus, which causes COVID-19, uses a viral surface spike protein for host cell entry and the human cell-surface transmembrane serine protease, TMPRSS2, to process the spike protein. Camostat mesylate, an orally available and clinically used serine protease inhibitor, inhibits TM...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kosinsky, Yuri, Peskov, Kirill, Stanski, Donald R., Wetmore, Diana, Vinetz, Joseph
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Society for Microbiology 2022
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9047529/ https://www.ncbi.nlm.nih.gov/pubmed/35412356 http://dx.doi.org/10.1128/spectrum.02167-21

Ejemplares similares

Camostat mesylate therapy in critically ill patients with COVID-19 pneumonia
por: Sakr, Yasser, et al.
Publicado: (2021)

Safety Evaluation and Population Pharmacokinetics of Camostat Mesylate and Its Major Metabolites Using a Phase I Study
por: Kim, Gwanyoung, et al.
Publicado: (2023)

Application of Semi-Mechanistic Pharmacokinetic and Pharmacodynamic Model in Antimicrobial Resistance
por: Mi, Kun, et al.
Publicado: (2022)

Camostat mesylate inhibits SARS-CoV-2 activation by TMPRSS2-related proteases and its metabolite GBPA exerts antiviral activity
por: Hoffmann, Markus, et al.
Publicado: (2020)

Camostat mesylate inhibits SARS-CoV-2 activation by TMPRSS2-related proteases and its metabolite GBPA exerts antiviral activity
por: Hoffmann, Markus, et al.
Publicado: (2021)

Camostat Mesylate May Reduce Severity of Coronavirus Disease 2019 Sepsis: A First Observation
por: Hofmann-Winkler, Heike, et al.
Publicado: (2020)

Quantitative Mechanistic Modeling in Support of Pharmacological Therapeutics Development in Immuno-Oncology
por: Peskov, Kirill, et al.
Publicado: (2019)

Inhibition of Listeria Monocytogenes HtrA Protease with Camostat, Gabexate and Nafamostat Mesylates and the Binding Mode of the Inhibitors
por: C, Amrutha M, et al.
Publicado: (2023)

Pharmacokinetics and pharmacodynamics of fenoldopam mesylate for blood pressure control in pediatric patients
por: Hammer, Gregory B, et al.
Publicado: (2008)

Low risk of the TMPRSS2 inhibitor camostat mesylate and its metabolite GBPA to act as perpetrators of drug-drug interactions
por: Weiss, Johanna, et al.
Publicado: (2021)

Radiation and PD-(L)1 treatment combinations: immune response and dose optimization via a predictive systems model
por: Kosinsky, Yuri, et al.
Publicado: (2018)

Efficacy and safety of camostat mesylate in early COVID-19 disease in an ambulatory setting: a randomized placebo-controlled phase II trial
por: Tobback, Els, et al.
Publicado: (2022)

Synthesis, Characterization, and Pharmacodynamics Study of Enrofloxacin Mesylate
por: Pei, Lin-lin, et al.
Publicado: (2020)

Structural insights and inhibition mechanism of TMPRSS2 by experimentally known inhibitors Camostat mesylate, Nafamostat and Bromhexine hydrochloride to control SARS-coronavirus-2: A molecular modeling approach
por: Sonawane, Kailas D., et al.
Publicado: (2021)

Individualized treatment strategies for hyperuricemia informed by a semi‐mechanistic exposure‐response model of uric acid dynamics
por: Aksenov, Sergey, et al.
Publicado: (2018)

A Phase 2 Randomized, Double-Blind, Placebo-controlled Trial of Oral Camostat Mesylate for Early Treatment of COVID-19 Outpatients Showed Shorter Illness Course and Attenuation of Loss of Smell and Taste
por: Chupp, Geoffrey, et al.
Publicado: (2022)

Camostat Mesylate Versus Lopinavir/Ritonavir in Hospitalized Patients With COVID-19—Results From a Randomized, Controlled, Open Label, Platform Trial (ACOVACT)
por: Karolyi, M., et al.
Publicado: (2022)

Camostat mesilate therapy for COVID-19
por: Uno, Yoshiharu
Publicado: (2020)

Role of T Cell-To-Dendritic Cell Chemoattraction in T Cell Priming Initiation in the Lymph Node: An Agent-Based Modeling Study
por: Azarov, Ivan, et al.
Publicado: (2019)

Cycle Network Model of Prostaglandin H Synthase-1
por: Goltsov, Alexey, et al.
Publicado: (2020)

Population pharmacokinetics–pharmacodynamics of sunitinib in pediatric patients with solid tumors
por: Wang, Erjian, et al.
Publicado: (2020)

A phase I study of high dose camostat mesylate in healthy adults provides a rationale to repurpose the TMPRSS2 inhibitor for the treatment of COVID‐19
por: Kitagawa, Junsaku, et al.
Publicado: (2021)

A semi-compartmental model describing the pharmacokinetic-pharmacodynamic relationship
por: Ki, Seunghee
Publicado: (2020)

Reconvalescent plasma/camostat mesylate in early SARS-CoV-2 Q-PCR positive high-risk individuals (RES-Q-HR): a structured summary of a study protocol for a randomized controlled trial
por: Keitel, Verena, et al.
Publicado: (2021)

The multistate tuberculosis pharmacometric model: a semi-mechanistic pharmacokinetic-pharmacodynamic model for studying drug effects in an acute tuberculosis mouse model
por: Chen, Chunli, et al.
Publicado: (2017)

Molecular mechanism of inhibiting the SARS-CoV-2 cell entry facilitator TMPRSS2 with camostat and nafamostat
por: Hempel, Tim, et al.
Publicado: (2020)

A Double-Blind, Randomized, Placebo-Controlled, Phase II Clinical Study To Evaluate the Efficacy and Safety of Camostat Mesylate (DWJ1248) in Adult Patients with Mild to Moderate COVID-19
por: Kim, Yeon-Sook, et al.
Publicado: (2022)

A Mechanistic In Vivo/Ex Vivo Pharmacokinetic‐Pharmacodynamic Model of Tenofovir for HIV Prevention
por: Jayachandran, Priya, et al.
Publicado: (2021)

Camostat Does Not Inhibit the Proteolytic Activity of Neutrophil Serine Proteases
por: Assylbekova, Akmaral, et al.
Publicado: (2022)

Clinical Pharmacokinetics and Pharmacodynamics of Dalcetrapib
por: Black, Donald M., et al.
Publicado: (2018)

Structural modeling and analysis of the SARS-CoV-2 cell entry inhibitor camostat bound to the trypsin-like protease TMPRSS2
por: Escalante, Diego E., et al.
Publicado: (2021)

Pharmacokinetic and Pharmacodynamic Effects of Polyclonal Antibodies against SARS-CoV2 in Mice
por: Jha, Aruni, et al.
Publicado: (2022)

Randomised controlled trial of intravenous nafamostat mesylate in COVID pneumonitis: Phase 1b/2a experimental study to investigate safety, Pharmacokinetics and Pharmacodynamics
por: Quinn, Tom M., et al.
Publicado: (2022)

Acute eosinophilic pneumonia caused by camostat mesilate: The first case report
por: Ota, Shinichiro, et al.
Publicado: (2016)

Pharmacokinetics and Pharmacodynamics of Posaconazole
por: Chen, Lu, et al.
Publicado: (2020)

Pharmacokinetics and Pharmacodynamics of Ibrexafungerp
por: McCarthy, Matthew William
Publicado: (2021)

Pharmacokinetics and Pharmacodynamics of Tedizolid
por: Iqbal, Khalid, et al.
Publicado: (2022)

Clinical Pharmacokinetics, Pharmacodynamics, and Immunogenicity of Anifrolumab
por: Tang, Weifeng, et al.
Publicado: (2023)

Precision Cardio-Oncology: Use of Mechanistic Pharmacokinetic and Pharmacodynamic Modeling to Predict Cardiotoxicities of Anti-Cancer Drugs
por: Wen, Hai-ni, et al.
Publicado: (2022)

Pharmacokinetics of eribulin mesylate in cancer patients with normal and impaired renal function
por: Tan, Antoinette R., et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_kvfq14mulsgce8rel24rfl3ujq